Investment Strategy Roundtable - Fueling the Future: Long-Term Fundraising Tactics for Biotech Innovators
🚀 Built to Last: Funding Biotech for the Long Haul
Effective Fundraising Strategies for Startups with Long Development Horizons
Bringing a biotech breakthrough to life is no small feat — and raising capital to fuel that journey can feel even more daunting. Long development cycles, regulatory uncertainty, and complex IP landscapes make traditional funding models challenging to navigate.
So how do you build a capital strategy that keeps you moving from preclinical to commercialization — without running out of steam (or cash)?
Join us for an engaging and actionable session where a seasoned biotech investor, a top-tier life sciences lawyer, and a commercialization strategist will come together to unpack how startups can design smart, staged fundraising strategies that match the long game of biotech. This is not your average panel — it’s a roadmap from the inside.
💡 We'll Explore:
Structuring your biotech startup for multi-phase fundraising
How to pitch long-horizon science to short-horizon investors
Legal frameworks and term sheets that protect you over time
IP considerations that make or break investor confidence
How and when to bring in non-dilutive funding
Aligning funding strategy with regulatory and go-to-market timelines
✅ Key Takeaways:
Understand the capital lifecycle of a biotech startup from seed to Series B and beyond
Learn how to position your startup for investor trust despite long timelines
Avoid the common legal and IP pitfalls that derail fundraising
Hear real stories of successful (and failed) biotech fundraising strategies
Get practical tips on blending dilutive and non-dilutive funding sources
👥 Who Should Attend:
Biotech founders raising Seed, Series A, or Growth rounds
Investors preparing for or actively navigating preclinical or early clinical trial milestones
Academic spinouts translating science into companies
🎤 Expert Facilitator:
Anna M. Detert - Principal, Gloucester Ventures
Pre-seed / seed investor in life sciences tools and advanced diagnostics companies, with focus on precision medicine.
Anna M. Detert brings 25+ years of experience in life sciences, spanning biopharma, diagnostics, venture capital, and private equity. She was most recently a Partner in KPMG UK's healthcare and life sciences strategy team, based in London. Anna has held consulting and leadership roles at KPMG, Prophet, and Xerox, specialising in commercialisation and growth strategy for pharmaceuticals and diagnostics. She started her career at Bayer Diagnostics (now Siemens) in product development and commercial. She holds an MBA from London Business School and a B.A. in Chemistry & French from Oberlin College.
Expert Guests:
Bill Cogan - Founder, Seven Legal
Bill is a dual-qualified lawyer, licensed in both England & Wales and New York, with a Master's degree from the University of California, Berkeley.
With over 15 years of experience across finance, energy, private equity, and venture capital, Bill blends legal expertise with a strong business mindset.
Stephanie Oestreich - Managing Director, Myeloma Investment Fund
Stephanie is also on the faculty of MIT, a member of SpringBoard Ventures, an advisor at grIP Venture Studio, to Biognosys (a Bruker company), Invitris, CART company CelineTx and to the drug development and investment company OrangeGrove Bio.
The Myeloma Investment Fund® (MIF) invests in companies developing innovative therapies and technologies with potential to transform myeloma patient outcomes.
Patrycja Maksymowicz - Commercial Strategist and Founder, CEO Sclr Labs
🧪 Hosted by:
Sclr Labs Innovation Hub in collaboration with Landmark
Dress Code: Smart casual
Dress code: smart casual
Event photography
By attending, you consent to being photographed for promotional use. If you'd prefer not to have your photos used or details shared, please let us know, and we’ll respect your preferences.
🚪Respect the Room
At sclr labs, we run on respect, for our speakers, for the founders who show up early, and for the momentum we’re building in the room.
When we say doors close at the start of the formal session, we mean it. Not because we’re strict, but because we’re serious.
Late arrivals miss context, break flow, and dilute energy. So plan ahead. Show up early. On time.